Skip to content
The Nexus
DossierENTITY

Matt Kaeberlein

Coverage of Matt Kaeberlein in the Nexus archive.

Earliest in view: Jun 18 · 11:30 UTCMost recent: Jun 18 · 11:30 UTC
Co-mentioned in this coverage
David Sinclairperson1Life Biosciencesorganization1cellular reprogrammingtopic1glaucomatopic1epigenetic reprogrammingtopic1National Institute on Aging's Division of Aging Biologyorganization1Felipe Sierraperson1
Recent coverage
  • HEALTHJun 18 · 11:30 UTCAXIOS
    Longevity medicine's do-or-die moment

    The first human trial of an experimental gene therapy aims to test the safety of cellular reprogramming to rejuvenate aging cells, with initial focus on treating glaucoma. The trial, sponsored by Life Biosciences co-founded by David Sinclair, represents a critical step in validating the potential of epigenetic reprogramming to address age-related diseases.

Matt Kaeberlein · Dossier · The Nexus